Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma

Regulatory T-cells (Tregs) play a major role in suppressing anti-tumor immune responses. Mogamulizumab, an anti-CC chemokine receptor type 4 (CCR4) monoclonal antibody, depletes effector Tregs (eTregs). However, the clinical efficacy of mogamulizumab was limited in phase Ia/Ib studies for solid tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Shoya, Suzuki, Susumu, Kondo, Yutaro, Okubo, Ikuko, Goto, Mitsuo, Ogawa, Tetsuya, Kato, Hidefumi, Ito, Hideaki, Takahara, Taishi, Satou, Akira, Tsuzuki, Toyonori, Yoshikawa, Kazuhiro, Nagao, Toru, Ueda, Ryuzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755268/
https://www.ncbi.nlm.nih.gov/pubmed/36522365
http://dx.doi.org/10.1038/s41598-022-22773-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755268/
https://www.ncbi.nlm.nih.gov/pubmed/36522365
http://dx.doi.org/10.1038/s41598-022-22773-1

Ejemplares similares